BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16820007)

  • 21. Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease.
    Desplats PA; Lambert JR; Thomas EA
    Neurobiol Dis; 2008 Sep; 31(3):298-308. PubMed ID: 18595722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRE-mediated transcription is increased in Huntington's disease transgenic mice.
    Obrietan K; Hoyt KR
    J Neurosci; 2004 Jan; 24(4):791-6. PubMed ID: 14749423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice.
    Gil JM; Mohapel P; Araújo IM; Popovic N; Li JY; Brundin P; Petersén A
    Neurobiol Dis; 2005 Dec; 20(3):744-51. PubMed ID: 15951191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.
    Gharami K; Xie Y; An JJ; Tonegawa S; Xu B
    J Neurochem; 2008 Apr; 105(2):369-79. PubMed ID: 18086127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholinergic neuronal defect without cell loss in Huntington's disease.
    Smith R; Chung H; Rundquist S; Maat-Schieman ML; Colgan L; Englund E; Liu YJ; Roos RA; Faull RL; Brundin P; Li JY
    Hum Mol Genet; 2006 Nov; 15(21):3119-31. PubMed ID: 16987871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.
    Bissonnette S; Vaillancourt M; Hébert SS; Drolet G; Samadi P
    PLoS One; 2013; 8(9):e75099. PubMed ID: 24040390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease.
    García-Martínez JM; Pérez-Navarro E; Xifró X; Canals JM; Díaz-Hernández M; Trioulier Y; Brouillet E; Lucas JJ; Alberch J
    J Neurosci Res; 2007 Sep; 85(12):2756-69. PubMed ID: 17387706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical localization of receptor for advanced glycation end (RAGE) products in the R6/2 mouse model of Huntington's disease.
    Anzilotti S; Giampà C; Laurenti D; Perrone L; Bernardi G; Melone MA; Fusco FR
    Brain Res Bull; 2012 Feb; 87(2-3):350-8. PubMed ID: 21272617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
    Schiefer J; Landwehrmeyer GB; Lüesse HG; Sprünken A; Puls C; Milkereit A; Milkereit E; Kosinski CM
    Mov Disord; 2002 Jul; 17(4):748-57. PubMed ID: 12210870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.
    Charvin D; Vanhoutte P; Pagès C; Borrelli E; Caboche J
    Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12218-23. PubMed ID: 16103364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retinal dysfunction, photoreceptor protein dysregulation and neuronal remodelling in the R6/1 mouse model of Huntington's disease.
    Batcha AH; Greferath U; Jobling AI; Vessey KA; Ward MM; Nithianantharajah J; Hannan AJ; Kalloniatis M; Fletcher EL
    Neurobiol Dis; 2012 Mar; 45(3):887-96. PubMed ID: 22198376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Light and electron microscopic characterization of the evolution of cellular pathology in the R6/1 Huntington's disease transgenic mice.
    Bayram-Weston Z; Jones L; Dunnett SB; Brooks SP
    Brain Res Bull; 2012 Jun; 88(2-3):104-12. PubMed ID: 21801812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice.
    Schilling G; Savonenko AV; Klevytska A; Morton JL; Tucker SM; Poirier M; Gale A; Chan N; Gonzales V; Slunt HH; Coonfield ML; Jenkins NA; Copeland NG; Ross CA; Borchelt DR
    Hum Mol Genet; 2004 Aug; 13(15):1599-610. PubMed ID: 15190011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential changes in striatal projection neurons in R6/2 transgenic mice for Huntington's disease.
    Sun Z; Del Mar N; Meade C; Goldowitz D; Reiner A
    Neurobiol Dis; 2002 Dec; 11(3):369-85. PubMed ID: 12586547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
    MacGibbon GA; Hamilton LC; Crocker SF; Costain WJ; Murphy KM; Robertson HA; Denovan-Wright EM
    J Neurosci Res; 2002 Feb; 67(3):372-8. PubMed ID: 11813242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease.
    Chen-Plotkin AS; Sadri-Vakili G; Yohrling GJ; Braveman MW; Benn CL; Glajch KE; DiRocco DP; Farrell LA; Krainc D; Gines S; MacDonald ME; Cha JH
    Neurobiol Dis; 2006 May; 22(2):233-41. PubMed ID: 16442295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease.
    Kung VW; Hassam R; Morton AJ; Jones S
    Neuroscience; 2007 Jun; 146(4):1571-80. PubMed ID: 17478055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain-specific factors in combination with mutant huntingtin induce gene-specific transcriptional dysregulation.
    Gomez GT; Hu H; McCaw EA; Denovan-Wright EM
    Mol Cell Neurosci; 2006 Apr; 31(4):661-75. PubMed ID: 16446101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1.
    Zucker B; Luthi-Carter R; Kama JA; Dunah AW; Stern EA; Fox JH; Standaert DG; Young AB; Augood SJ
    Hum Mol Genet; 2005 Jan; 14(2):179-89. PubMed ID: 15548548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients.
    Laprairie RB; Warford JR; Hutchings S; Robertson GS; Kelly ME; Denovan-Wright EM
    J Neuroimmunol; 2014 Feb; 267(1-2):61-72. PubMed ID: 24360910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.